Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2025-04-28 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "董事会审计委员会2024年度履职情况报告" which translates to "Board Audit Committee 2024 Annual Performance Report." It details the audit committee's activities, meetings, evaluations of external auditors, internal audit guidance, and overall assessment for the year 2024. The content focuses on the audit committee's duties and oversight rather than presenting full financial statements or audit opinions themselves. The document length is 2683 characters, which is relatively short and more consistent with a committee report rather than a full audit report or annual report. It is not a certification or a brief announcement but a detailed report on the audit committee's work. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2024
2025-04-28 Chinese
第五届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the fourth meeting of the fifth Supervisory Board of Yunnan Biological Valley Pharmaceutical Co., Ltd. It includes meeting details, voting results, and summaries of various agenda items such as the 2024 Supervisory Board Work Report, 2025 Business Plan, 2024 Financial Statements, 2025 Financial Budget, and other related reports. The document references multiple reports and announcements that are separately published on the Beijing Stock Exchange website, indicating that this document itself is a meeting resolution announcement rather than the reports themselves. The content focuses on the supervisory board's meeting decisions and approvals, which aligns with the category of Board/Management Information (MANG). The document is over 7,000 characters and contains substantive content about board resolutions, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is MANG (Board/Management Information).
2025-04-28 Chinese
第五届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the fifth board of directors of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the 2024 board work report, independent directors' reports, financial statements, audit reports, internal control reports, remuneration plans, and other corporate governance matters. The document references various reports and announcements that are separately disclosed on the Beijing Stock Exchange website, indicating that this document itself is a board meeting resolution announcement rather than the reports themselves. The document is lengthy (over 12,000 characters) and contains detailed board meeting procedural information, voting results, and agenda approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. It is not the full annual report (10-K), audit report (AR), or other report types, but a board meeting resolution announcement.
2025-04-28 Chinese
关于预计2025年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2025 by Yunnan Shengwu Valley Pharmaceutical Co., Ltd. It details the nature, amounts, and reasons for these transactions, along with the approval process by the board and committees. The document is relatively short (2810 characters) and focuses on disclosure of anticipated related party dealings rather than presenting financial statements or detailed financial performance. It does not contain comprehensive financial data or results, nor is it a report or transcript. It is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Annual Report, Interim Report, or Capital Update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-04-28 Chinese
董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (信永中和) for the 2024 fiscal year audit. It details the audit firm's qualifications, the audit process, communication with management, and the committee's evaluation of the audit firm's performance. The document includes references to the audit report issuance, internal control audit, and the committee's oversight activities. It is not the audit report itself but a supervisory report on the audit firm's performance and compliance with auditing standards. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length is 2320 characters, which is consistent with a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2024
2025-04-28 Chinese
关于拟设立上海分公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to establish a new branch office in Shanghai. It includes details about the branch, the purpose of establishment, and the impact on the company. It is a formal announcement approved by the board of directors but does not contain financial data, audit information, or detailed management reports. It is not a report or presentation but a regulatory announcement about a corporate action. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.